Table 4.
Lifetime model results for treatment with tiotropium + olodaterol vs with tiotropium monotherapy
| Tiotropium + olodaterol | Tiotropium | |
|---|---|---|
| Severe exacerbation rate per year | 0.163 | 0.187 |
| Total exacerbation rate per year | 0.724 | 0.786 |
| Pneumonia per year | 0.039 | 0.040 |
| Remaining life-expectancy since start of the simulation (years) | 9.94 | 9.84 |
| Annual decline in lung function (mL) | −38.3 | −38.3 |
| Annual change in exercise capacity (seconds) | −4.4 | −4.6 |
| Annual change in physical activity (SGRQ activity score in points) | +1.52 | +1.53 |
| Percentage of time periods with cough/sputum, % | 66.1 | 66.2 |
| Percentage of time periods with breathlessness, % | 70.5 | 70.9 |
| Annual change in disease-specific quality of life (SGRQ total score in points) | +1.03 | +1.04 |
| Total number of QALYs (discounted) | 4.80 | 4.76 |
| Total lifetime costs from the National Sickness Fund perspective (discounted) | €22,161 | €22,433 |
| Total lifetime costs from the societal perspective (discounted) | €25,606 | €25,483 |
Abbreviations: QALYs, quality-adjusted life-years; SGRQ, St George’s Respiratory Questionnaire.